Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism - PubMed (original) (raw)
Clinical Trial
. 2002 Sep;87(9):4128-36.
doi: 10.1210/jc.2002-020518.
Affiliations
- PMID: 12213860
- DOI: 10.1210/jc.2002-020518
Clinical Trial
Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism
Nelly Pitteloud et al. J Clin Endocrinol Metab. 2002 Sep.
Abstract
GnRH treatment is successful in inducing virilization and spermatogenesis in men with idiopathic hypogonadotropic hypogonadism (IHH). However, a small subset of IHH men, poorly characterized to date, fail to reach a normal testicular volume (TV) and produce sperm on this therapy. To determine predictors of outcome in terms of TV and sperm count, we studied 76 IHH men (38% with anosmia) undergoing GnRH therapy for 12-24 months. The population was stratified according to the baseline degree of prior pubertal development: absent (group 1, n = 52), partial (group 2, n = 18), or complete (adult onset HH; group 3, n = 6). Cryptorchidism was recorded in 40% of group 1, 5% of group 2, and none in group 3. Pulsatile GnRH therapy was initiated at 5-25 ng/kg per pulse sc and titrated to attain normal adult male testosterone (T) levels. LH, FSH, T, and inhibin B (I(B)) levels were measured serially, and maximum sperm count was recorded. A longitudinal mixed effects model was used to determine predictors of final TV. LH (97%) and T (93%) levels were normalized in the majority of IHH men. Groups 2 and 3 achieved a normal adult testicular size (92%), FSH (96%), I(B) levels (93%), and sperm in their ejaculate (100%). However, given their prior complete puberty and thus primed gonadotropes and testes, group 3 responded faster, normalizing androgen production by 2 months and completing spermatogenesis by 6 months. In contrast, group 1 failed to normalize TV (11 +/- 0.4 ml) and I(B) levels (92 +/- 6 pg/ml) by 24 months, despite normalization of their FSH levels (11 +/- 2 IU/liter). Similarly, sperm counts of group 1 plateaued well below the normal range (median of 3 x 10(6)/ml) with 18% remaining azoospermic. The independent predictors of outcome of long-term GnRH therapy were: 1) the presence of some prior pubertal development (positive predictor; group effect (beta) = 4.3; P = 0.003); 2) a baseline I(B) less than 60 pg/ml (negative predictor; beta = -3.7; P = 0.009); and 3) prior cryptorchidism (negative predictor; beta = -1.8; P = 0.05). Notably, anosmia was not an independent predictor of outcome when adjusted for other baseline variables. Our conclusions are: 1) pulsatile GnRH therapy in IHH men is very successful in inducing androgen production and spermatogenesis; 2) normalization of the LH-Leydig cell-T axis is achieved more uniformly than the FSH-Sertoli cell-I(B) axis during GnRH therapy; and 3) favorable predictors for achieving an adult testicular size and consequently optimizing spermatogenesis are prior history of sexual maturation, a baseline I(B) greater than 60 pg/ml, and absence of cryptorchidism.
Similar articles
- Inhibin B in males with gonadotropin-releasing hormone (GnRH) deficiency: changes in serum concentration after shortterm physiologic GnRH replacement--a clinical research center study.
Seminara SB, Boepple PA, Nachtigall LB, Pralong FP, Khoury RH, Sluss PM, Lecain AE, Crowley WF Jr. Seminara SB, et al. J Clin Endocrinol Metab. 1996 Oct;81(10):3692-6. doi: 10.1210/jcem.81.10.8855824. J Clin Endocrinol Metab. 1996. PMID: 8855824 - Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes.
Sykiotis GP, Hoang XH, Avbelj M, Hayes FJ, Thambundit A, Dwyer A, Au M, Plummer L, Crowley WF Jr, Pitteloud N. Sykiotis GP, et al. J Clin Endocrinol Metab. 2010 Jun;95(6):3019-27. doi: 10.1210/jc.2009-2582. Epub 2010 Apr 9. J Clin Endocrinol Metab. 2010. PMID: 20382682 Free PMC article. - Hormonal control of spermatogenesis in men: therapeutic aspects in hypogonadotropic hypogonadism.
Pitteloud N, Dwyer A. Pitteloud N, et al. Ann Endocrinol (Paris). 2014 May;75(2):98-100. doi: 10.1016/j.ando.2014.04.002. Epub 2014 Apr 29. Ann Endocrinol (Paris). 2014. PMID: 24793994 Review. - Long-term outcome of idiopathic hypogonadotropic hypogonadism.
King TF, Hayes FJ. King TF, et al. Curr Opin Endocrinol Diabetes Obes. 2012 Jun;19(3):204-10. doi: 10.1097/MED.0b013e328353565b. Curr Opin Endocrinol Diabetes Obes. 2012. PMID: 22499222 Review.
Cited by
- Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism.
Dwyer AA, McDonald IR, Quinton R. Dwyer AA, et al. Ann N Y Acad Sci. 2024 Oct;1540(1):133-146. doi: 10.1111/nyas.15214. Epub 2024 Aug 27. Ann N Y Acad Sci. 2024. PMID: 39190467 Review. - Classes and predictors of reversal in male patients with congenital hypogonadotropic hypogonadism: a cross-sectional study of six international referral centres.
Dwyer AA, McDonald IR, Cangiano B, Giovanelli L, Maione L, Silveira LFG, Raivio T, Latronico AC, Young J, Quinton R, Bonomi M, Persani L, Seminara SB, Lee CS. Dwyer AA, et al. Lancet Diabetes Endocrinol. 2024 Apr;12(4):257-266. doi: 10.1016/S2213-8587(24)00028-7. Epub 2024 Mar 1. Lancet Diabetes Endocrinol. 2024. PMID: 38437850 - Mini-Puberty, Physiological and Disordered: Consequences, and Potential for Therapeutic Replacement.
Rohayem J, Alexander EC, Heger S, Nordenström A, Howard SR. Rohayem J, et al. Endocr Rev. 2024 Jul 12;45(4):460-492. doi: 10.1210/endrev/bnae003. Endocr Rev. 2024. PMID: 38436980 Free PMC article. Review. - Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis.
Alexander EC, Faruqi D, Farquhar R, Unadkat A, Ng Yin K, Hoskyns R, Varughese R, Howard SR. Alexander EC, et al. Eur J Endocrinol. 2024 Jan 3;190(1):S1-S11. doi: 10.1093/ejendo/lvad166. Eur J Endocrinol. 2024. PMID: 38128110 Free PMC article. - Clinical Manifestations, Genetic Variants and Therapeutic Evaluation in Sporadic Chinese Patients with Idiopathic Hypogonadotropic Hypogonadism.
He D, Sun H, Zhang M, Li Y, Liu F, Zhang Y, He M, Ban B. He D, et al. Int J Gen Med. 2023 Sep 29;16:4429-4439. doi: 10.2147/IJGM.S430904. eCollection 2023. Int J Gen Med. 2023. PMID: 37799300 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- P30 HD028138/HD/NICHD NIH HHS/United States
- R01 HD015788/HD/NICHD NIH HHS/United States
- U54 HD029164/HD/NICHD NIH HHS/United States
- U54DK07028-24/DK/NIDDK NIH HHS/United States
- U54-HD-28138/HD/NICHD NIH HHS/United States
- R01 HD15788/HD/NICHD NIH HHS/United States
- U54 HD028138/HD/NICHD NIH HHS/United States
- M01-RR-01066/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources